News & Perspective

Feb 21, 2013

Feb 21, 2013

CDC midseason check finds scant flu vaccine effect for seniors

(CIDRAP News) – Influenza vaccine over the past few months has provided moderate protection overall but didn't have a significant impact on protecting seniors, a study from the US Centers for Disease Control and Prevention (CDC) revealed today.

Jan 11, 2013

Jan 11, 2013

CDC's early-season look finds flu vaccine 62% effective

(CIDRAP News) – An early assessment of this year's influenza vaccine shows it has provided a "moderate" level of protection at 62% so far this season, the Centers for Disease Control and Prevention (CDC) said today. That vaccine effectiveness (VE) level is about the same as in recent seasons and as found in a recent careful meta-analysis of randomized controlled trials.

Oct 15, 2012

Oct 15, 2012

Report: Complacency, misperception stymie quest for better flu vaccines

The world needs much better influenza vaccines, but the quest for them faces a formidable barrier: overconfidence about the effectiveness of existing influenza vaccines.

Oct 25, 2011

Oct 25, 2011

Strict meta-analysis raises questions about flu vaccine efficacy

Editor’s Note: This article covers research conducted in part by CIDRAP researchers. Please note that CIDRAP News operates independently in relation to CIDRAP's research and policy programs.

See also: Public health groups say flu vaccine is best tool, despite limitations

Oct 06, 2010

Oct 06, 2010

Trial answers some, not all, questions on cell-based flu vaccines

(CIDRAP News) – A new report says that a cell culture derived influenza vaccine and a conventional egg-based vaccine both proved effective in a large international clinical trial, offering support for those who contend that cell-based vaccines should become an important part of flu vaccine supplies in coming years.

Sep 22, 2009

Sep 22, 2009

Business conference airs challenges of H1N1 vaccine campaign

(CIDRAP News) – With the second wave of the H1N1 influenza virus now hitting, much of the response toe the pandemic is focused on the development and distribution of an effective vaccine, a project that poses many challenges and uncertainties.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Nov 02, 2006

Nov 02, 2006

WHO report calls H5N1 vaccine stockpiling premature

(CIDRAP News) – A group of influenza experts convened by the World Health Organization cautioned today that governments shouldn't stockpile "pre-pandemic" H5N1 influenza vaccines now, because too little is known about the requirements for an effective vaccine.

Oct 04, 2006

Oct 04, 2006

Groups call for pandemic flu vaccine 'master plan'

(CIDRAP News) – Public health and infectious disease experts today called on the United States to develop a "master plan" for development of pandemic influenza vaccines in order to translate scientific advances more rapidly into improved pandemic preparedness.

Mar 07, 2006

Mar 07, 2006

HHS using Indonesian strain for second H5N1 flu vaccine

(CIDRAP News) – A second vaccine against human H5N1 influenza is being developed, US Health and Human Services (HHS) Secretary Mike Leavitt announced yesterday.

In a speech at an immunization conference, Leavitt announced that he has authorized the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) to start work on a second vaccine, according to an Associated Press (AP) report published yesterday.

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»